dzif-10c
mAbexperimental
Clinical trial activity
2 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Nov 23, 2020 (NCT04631705)
Timeline
2020s
- Jan 1, 2020
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- SARS-CoV-2Immunity, passive
SARS-CoV-2 immunity, passive
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04631666 | Phase 1/Phase 2 (Phase 2) | Nov 23, 2020 | Boehringer Ingelheim, University of Cologne, ZKS Köln |
| NCT04631705 | Phase 1/Phase 2 (Phase 2) | Nov 23, 2020 | Boehringer Ingelheim, University of Cologne |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Boehringer Ingelheim | For profit | 2 | 0 | 1 | 2020 |
| University of Cologne | Academic/Hospital | 2 | 2 | 1 | 2020 |
| ZKS Köln | Academic/Hospital | 1 | 0 | 1 | 2020 |
3 organizations
Page 1 / 1